Melatonin Attenuates Memory Impairment, Amyloid- β Accumulation, and Neurodegeneration in a Rat Model of Sporadic Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 47, Issue 1, 2015, Pages 103-116

  Rudnitskaya, Ekaterina A ^a   Muraleva, Natalia A ^a   Maksimova, Kseniya Yi ^b   Kiseleva, Elena ^a   Kolosova, Nataliya G ^a,c,d   Stefanova, Natalia A ^a  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^c Institute of Mitoengineering   (Russian Federation)

^d NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

Author keywords

Alzheimer's disease; Melatonin; Neurodegeneration; Senescence accelerated OXYS rats

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; MELATONIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN LEVEL; CELL VOLUME; CONTROLLED STUDY; DENTATE GYRUS; DETERIORATION; DISEASE COURSE; DISEASE SEVERITY; FRONTAL CORTEX; GENOTYPE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; MALE; MEMORY DISORDER; MITOCHONDRION; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REFERENCE MEMORY; ULTRASTRUCTURE; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; GENETICS; HIPPOCAMPUS; HUMAN; MAZE TEST; MEMORY DISORDERS; METABOLISM; MUTATION; NEURODEGENERATIVE DISEASES; ORAL DRUG ADMINISTRATION; PATHOLOGY; TRANSGENIC RAT; WISTAR RAT;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; HIPPOCAMPUS; HUMANS; MAZE LEARNING; MELATONIN; MEMORY DISORDERS; MUTATION; NEURODEGENERATIVE DISEASES; NEURONS; PRESENILIN-1; PRESENILIN-2; RATS; RATS, TRANSGENIC; RATS, WISTAR;

EID: 84940915132     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150161     Document Type: Article

References (47)

1. Moodley KK, Chan D (2014) The hippocampus in neurodegenerative disease. Front Neurol Neurosci 34, 95-108.
2. Liu J, Qiu J, Wang M, Wang L, Su L, Gao J, Gu Q, Xu J, Huang SL, Gu LQ, Huang ZS, Li D (2014) Synthesis and characterization of 1H-phenanthro[9,10-d]imidazole derivatives as multifunctional agents for treatment of Alzheimer's disease. Biochim Biophys Acta 1840, 2886-2903.
3. Saito S, Ihara M (2014) New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci 6, 290.
4. Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, Del Ser T (2015) A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis 45, 75-88.
5. Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, Kook KA, Harrington CR (2015) Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 44, 705-720.
6. Chen Y, Sun J, Fang L, Liu M, Peng S, Liao H, Lehmann J, ZhangY(2012) Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J Med Chem 55, 4309-4321.
7. Bush AI, Tanzi RE (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5, 421-432.
8. Swaminathan A, Jicha GA (2014) Nutrition and prevention of Alzheimer's dementia. Front Aging Neurosci 6, 282.
9. Jicha GA, Carr SA (2010) Conceptual evolution in Alzheimer's disease: Implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis 19, 253-272.
10. Bubenik GA, Konturek SJ (2011) Melatonin and aging: Prospects for human treatment. J Physiol Pharmacol 62, 13-19.
11. HardelandR(2012) Melatonin in aging and disease - multiple consequences of reduced secretion, options and limits of treatment. Aging Dis 3, 194-225.
12. Eisenberg DP, Kohn PD, Baller EB, Bronstein JA, Masdeu JC, Berman KF (2010) Seasonal effects on human striatal presynaptic dopamine synthesis. J Neurosci 30, 14691-14694.
13. Jung-Hynes B, Reiter RJ, Ahmad N (2010) Sirtuins, melatonin and circadian rhythms: Building a bridge between aging and cancer. J Pineal Res 48, 9-19.
14. Belancio VP, Blask DE, Deininger P, Hill SM, Jazwinski SM (2015) The aging clock and circadian control of metabolism and genome stability. Front Genet 5, 455.
15. Reiter RJ, Tan D-X, Osuna C, Gitto E (2000) Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 7, 444-458.
16. Hardeland R (2010) Melatonin metabolism in the central nervous system. Curr Neuropharmacol 8, 168-181.
17. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ (1993) Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocrine J 1, 57-60.
18. Shukla M, Htoo HH, Wintachai P, Hernandez JF, Dubois C, Postina R, Xu H, Checler F, Smith DR, Govitrapong P, Vincent B (2015) Melatonin stimulates the nonamyloidogenic processing of -APP through the positive transcriptional regulation ofADAM10 andADAM17. J Pineal Res 58, 151-165.
19. Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J (1998) Inhibition of Alzheimer - fibrillogenesis by melatonin. J Biol Chem 273, 7185-7188.
20. Poeggeler B, Miravalle L, Zagorski MG,WisniewskiT, Chyan YJ, Zhang Y, Shao H, Bryant-Thomas T, Vidal R, Frangione B, Ghiso J, Pappolla MA (2001) Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid A- peptide. Biochemistry 40, 14995-5001.
21. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter RJ, Efthimiopoulos S, Robakis NK (1997) Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 17, 1683-1690.
22. Cheng X, van Breemen RB (2005) Mass spectrometry-based screening for inhibitors of beta-amyloid protein aggregation. Anal Chem 77, 7012-7015.
23. Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q (2013) Melatonin in Alzheimer's disease. Int J Mol Sci 14, 14575-14593.
24. Reiter R, Tang L, Garcia JJ, Muñoz-Hoyos A (1997) Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci 60, 2255-2271.
25. Briady N, Muñoz P, Palacios AG, Castellano-Gonzalez G, Inestrosa NC, Chung RS, Sachdev P, Guillemin GJ (2012) Recent rodent models for Alzheimer's disease: Clinical implications and basic research. J Neural Transm 119, 173-195.
26. Castellano JM, Deane R, Gottesdiener AJ, Verghese Ph B, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM (2012) Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood A- clearance in a mouse model of -amyloidosis. Proc Natl Acad Sci U S A 109, 15502-15507.
27. Kozhevnikova OS, Korbolina EE, Stefanova NA, Muraleva NA, Orlov YL, Kolosova NG (2013) Association of AMDlike retinopathy development with an Alzheimer's disease metabolic pathway in OXYS rats. Biogerontology 14, 753-762.
28. Stefanova NA, Kozhevnikova OS, Vitovtov AO, Maksimova KYi, Logvinov SV, Rudnitskaya EA, Korbolina EE, Muraleva NA, Kolosova NG (2014) Senescence-accelerated OXYS rats: A model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease. Cell Cycle 13, 898-909.
29. Stefanova NA, Muraleva NA, Skulachev VP, Kolosova NG (2014) Alzheimer's disease-like pathology in senescenceaccelerated OXYS rats can be partially retarded with mitochondria-targeted antioxidant SkQ1. J Alzheimers Dis 38, 681-694.
30. Stefanova NA, Muraleva NA, Korbolina EE, Kiseleva E, Maksimova KY, Kolosova NG (2015) Amyloid accumulation is a late event in sporadic Alzheimer's disease-like pathology in nontransgenic rats. Oncotarget 6, 1396-1413.
31. Stefanova NA, Fursova AZh,KolosovaNG(2010) Behavioral effects induced by mitochondria-targeted antioxidant SkQ1 in Wistar and senescence-accelerated OXYS rats. J Alzheimers Dis 21, 479-491.
32. Stefanova NA, Fursova AZh, Sarsenbaev KN, Kolosova NG (2011) Effects of Cistanche deserticola on behavior and signs of cataract and retinopathy in senescence-accelerated OXYS rats. J Ethnopharmacol 138, 624-632.
33. Rudnitskaya EA, Maksimova KY, Muraleva NA, Logvinov SV,Yanshole LV,Kolosova NG, StefanovaNA(2015) Beneficial effects of melatonin in a rat model of sporadic Alzheimer's disease. Biogerontology 16(3), 303-316.
34. Paxinos G, Watson CH (2007) The Rat Brain in Stereotaxic Coordinates, Sixth Edition, Elsevier, Sydney.
35. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11, 47-60.
36. Miller E, Morel A, Saluk J (2015) Melatonin redox activity. Its potential clinical application in neurodegenerative disorders. Curr Top Med Chem 15, 163-169.
37. Cacucci F, Yi M, Wills TJ, Chapman P, O'Keefe J (2008) Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. Proc Natl Acad Sci U S A 105, 7863-7868.
38. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid -peptide in the brain and cognitive decline. JAMA 283, 1571-1577.
39. Holtzman DM, Morris JC, Goate A (2011) Alzheimer's disease: The challenge of the second century. Sci Transl Med 3, 77sr1.
40. Jakob-Roetne R, Jacobsen H (2009) Alzheimer's disease: From pathology to therapeutic approaches. Angew Chem Int Ed Engl 48, 3030-3059.
41. Matsubara E, Bryant-Thomas T, Quinto JP, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan Y-J, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikgbal I, Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 85, 1101-1108.
42. Quinn J, Kulhanek D, Nowlin J, Jones R, Praticò D, Rokach J, Stackman R (2005) Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: Implications for clinical trials. Brain Res 1037, 209-213.
43. Scheff SW, Price DA (2006) Alzheimer's disease-related alterations in synaptic density: Neocortex and hippocampus. J Alzheimers Dis 9, 101-115.
44. Andersen P, Morris R, Amaral D, Bliss T, O'Kneefe J (2007) The Hippocampus Book. Oxford University Press Inc., New York.
45. Mattson MP, Gleichmann M, Cheng A (2008) Mitochondria in neuroplasticity and neurological disorders. Neuron 60, 748-766.
46. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
47. Pappolla MA, Chyan YJ, Poeggeler B, Bozner P, Ghiso J, LeDoux SP,Wilson GL (1999) Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: Prevention by melatonin. J Pineal Res 27, 226-229.